No benefit of a structured treatment interruption based on genotypic resistance in heavily pretreated HIV-infected patients

AIDS

Volumn 19, Issue 15, 2005, Pages 1643-1647

  Ghosn, Jade ^a,c   Wirden, Marc ^a   Ktorza, Nadine ^a   Peytavin, Gilles ^b   Aït Mohand, Hocine ^a,c   Schneider, Luminita ^a,c   Dominguez, Stéphanie ^a,c   Bricaire, François ^a   Calvez, Vincent ^a   Costagliola, Dominique ^c   Katlama, Christine ^a,c  

^a PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^b BICHAT HOSPITAL   (France)

^c INSERM   (France)

Author keywords

Genotypic resistance; Salvage; Structured treatment interruption; Treatment failure

Indexed keywords

ABACAVIR; AMPRENAVIR; DELAVIRDINE; DIDANOSINE; EFAVIRENZ; INDINAVIR; LAMIVUDINE; LOPINAVIR; NEVIRAPINE; PROTEINASE INHIBITOR; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; TENOFOVIR;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ARTICLE; CELL COUNT; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG SENSITIVITY; GENE MUTATION; GENETIC RESISTANCE; GENOTYPE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LONGITUDINAL STUDY; PREMEDICATION; PRIORITY JOURNAL; SALVAGE THERAPY; TREATMENT FAILURE; VIRUS LOAD; VIRUS RESISTANCE; VIRUS STRAIN;

EID: 27144521249     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.aids.0000181322.17679.b2     Document Type: Article

References (24)

1. Palella FJ Jr, Delaney KM, Moorman AC, Loveless MO, Fuhrer J, Satten GA, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med 1998; 338:853-860.
2. Ledergerber B, Egger M, Opravil M, Telenti A, Hirschel B, Battegay M, et al. Clinical progression and virological failure on highly active antiretroviral therapy in HIV-1 patients: a prospective cohort study. Swiss HIV Cohort Study. Lancet 1999; 353:863-868.
3. Mocroft A, Devereux H, Kinloch-de-Loes S, Wilson D, Madge S, Youle M, et al. Immunological, virological and clinical response to highly active antiretroviral therapy treatment regimens in a complete clinic population. Royal Free Centre for HIV Medicine. AIDS 2000; 14:1545-1552.
4. Richman D, Morton S, Wrin T, Hellmann N, Berry S, Shapiro M, et al. The prevalence of antiretroviral drug resistance in the United States. AIDS 2004; 18:1393-1401.
5. Delfraissy JF. Prise en Charge thérapeutique des Personnes infectées par le HIV. Paris: Médecine-Sciences Flammarion edn; 2004.
6. Harrigan PR, Larder BA. Extent of cross-resistance between agents used to treat human immunodeficiency virus type 1 infection in clinically derived isolates. Antimicrob Agents Chemother 2002; 46:909-912.
7. Miller V, Sabin C, Hertogs K, Bloor S, Martinez-Picado J, D'Aquila R, et al. Virological and immunological effects of treatment interruptions in HIV-1 infected patients with treatment failure. AIDS 2000; 14:2857-2867.
8. Deeks SG, Wrin T, Liegler T, Hoh R, Hayden M, Barbour JD, et al. Virologic and immunologic consequences of discontinuing combination antiretroviral-drug therapy in HIV-infected patients with detectable viremia. N Engl J Med 2001; 344:472-480.
9. Lisziewicz J, Rosenberg E, Lieberman J, Jessen H, Lopalco L, Siliciano R, et al. Control of HIV despite the discontinuation of antiretroviral therapy. N Engl J Med 1999; 340:1683-1684.
10. Lawrence J, Mayers DL, Hullsiek KH, Collins G, Abrams DI, Reisler RB, et al. Structured treatment interruption in patients with multidrug-resistant human immunodeficiency virus. N Engl J Med 2003; 349:837-846.
11. Ruiz L, Ribera E, Bonjoch A, Romeu J, Martinez-Picado J, Paredes R, et al. Role of structured treatment interruption before a 5-drug salvage antiretroviral regimen: the Retrogene Study. J Infect Dis 2003; 188:977-985.
12. Katlama C, Dominguez S, Gourlain K, Duvivier C, Delaugerre C, Legrand M, et al. Benefit of treatment interruption in HIV-infected patients with multiple therapeutic failures: a randomized controlled trial (ANRS 097). AIDS 2004; 18:217-226.
13. Benson C, Downey G, Havlir DV, Vaida F, Lederman M, Gulick R, et al. A 16-week treatment interruption does not improve the virologic response to multidrug salvage therapy in treatment-experienced patients: 48-week results from ACTG A5086. Eleventh Conference on Retroviruses and Opportunistic Infections. San Francisco, February 2004 [abstract 58].
14. Deeks SG. Treatment of antiretroviral-drug-resistant HIV-1 infection. Lancet 2003; 362:2002-2011.
15. Launay O, Duval X, Dalban C, Descamps D, Peytavin G, Certain A, et al. Lowering drug pressure to stabilize multidrug resistant HIV evolution and pathogenecity (Vista ANRS 109). Eleventh Conference on Retroviruses and Opportunistic Infections. San Francisco, February 2004 [abstract 649].
16. Devereux HL, Youle M, Johnson MA, Loveday C. Rapid decline in detectability of HIV-1 drug resistance mutations after stopping therapy. AIDS 1999; 13:F123-F127.
17. Delaugerre C, Valantin MA, Mouroux M, Bonmarchand M, Carcelain G, Duvivier C, et al. Re-occurrence of HIV-1 drug mutations after treatment re-initiation following interruption in patients with multiple treatment failure. AIDS 2001; 15:2189-2191.
18. Mouroux M, Yvon-Groussin A, Peytavin G, Delaugerre C, Legrand M, Bossi P, et al. Early virological failure in naive human immunodeficiency virus patients receiving saquinavir (soft gel capsule)-stavudine-zalcitabine (MIKADO trial) is not associated with mutations conferring viral resistance. J Clin Microbiol 2000; 38:2726-2730.
19. Hirsch MS, Brun-Vezinet F, D'Aquila RT, Hammer SM, Johnson VA, Kuritzkes DR, et al. Antiretroviral drug resistance testing in adult HIV-1 infection: recommendations of an International AIDS Society-USA Panel. JAMA 2000; 283:2417-2426.
20. DeGruttola V, Dix L, D'Aquila R, Holder D, Phillips A, Ait-Khaled M, et al. The relation between baseline HIV drug resistance and response to antiretroviral therapy: re-analysis of retrospective and prospective studies using a standardized data analysis plan. Antivir Ther 2000; 5:41-48.
21. Ghosn J, Viard JP, Katlama C, de Almeida M, Tubiana R, Letourneur F, et al. Evidence of genotypic resistance diversity of archived and circulating viral strains in blood and semen of pre-treated HIV-infected men. AIDS 2004; 18:447-457.
22. Lambotte O, Chaix ML, Gubler B, Nasreddine N, Wallon C, Goujard C, et al. The lymphocyte HIV reservoir in patients on long-term HAART is a memory of virus evolution. AIDS 2004; 18:1147-1158.
23. Miller V, Phillips AN, Clotet B, Mocroft A, Ledergerber B, Kirk O, et al. Association of virus load, CD4 cell count, and treatment with clinical progression in human immunodeficiency virus-infected patients with very low CD4 cell counts. J Infect Dis 2002; 186:189-197.
24. Ledergerber B, Lundgren JD, Walker AS, Sabin C, Justice A, Reiss P, et al. Predictors of trend in CD4-positive T-cell count and mortality among HIV-1-infected individuals with virological failure to all three antiretroviral-drug classes. Lancet 2004; 364:51-62.